WO2020223392A3 - Compositions d'anticorps associés au cancer et méthodes d'utilisation - Google Patents

Compositions d'anticorps associés au cancer et méthodes d'utilisation Download PDF

Info

Publication number
WO2020223392A3
WO2020223392A3 PCT/US2020/030534 US2020030534W WO2020223392A3 WO 2020223392 A3 WO2020223392 A3 WO 2020223392A3 US 2020030534 W US2020030534 W US 2020030534W WO 2020223392 A3 WO2020223392 A3 WO 2020223392A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methods
antigen
cancer associated
antibody compositions
Prior art date
Application number
PCT/US2020/030534
Other languages
English (en)
Other versions
WO2020223392A2 (fr
Inventor
Daniele Biasci
Goran Rakocevic
Berke Cagkan TOPTAS
Ines DE SANTIAGO DOMINGOS DE JESUS
Original Assignee
Totient, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Totient, Inc. filed Critical Totient, Inc.
Priority to SG11202111672RA priority Critical patent/SG11202111672RA/en
Priority to JP2021564804A priority patent/JP2022530667A/ja
Priority to CN202080048070.8A priority patent/CN114127114A/zh
Priority to US17/606,246 priority patent/US20220204643A1/en
Priority to EP20798045.9A priority patent/EP3962953A4/fr
Priority to CA3138550A priority patent/CA3138550A1/fr
Priority to AU2020266560A priority patent/AU2020266560A1/en
Publication of WO2020223392A2 publication Critical patent/WO2020223392A2/fr
Publication of WO2020223392A3 publication Critical patent/WO2020223392A3/fr
Priority to IL287342A priority patent/IL287342A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouveaux anticorps associés au cancer et de nouveaux fragments de liaison à un antigène qui sont utilisés dans le diagnostic d'un cancer ou d'une métastase associée. L'invention concerne de nouveaux anticorps associés au cancer et de nouveaux fragments de liaison à un antigène qui sont utilisés dans le traitement d'un cancer ou d'une métastase associée. L'invention concerne un nouveau récepteur antigénique chimérique ou une protéine de fusion de récepteur de lymphocytes T qui comprend un ou plusieurs domaines de liaison à un antigène associés au cancer qui sont utiles pour le traitement d'un cancer.
PCT/US2020/030534 2019-04-30 2020-04-29 Compositions d'anticorps associés au cancer et méthodes d'utilisation WO2020223392A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SG11202111672RA SG11202111672RA (en) 2019-04-30 2020-04-29 Cancer associated antibody compositions and methods of use
JP2021564804A JP2022530667A (ja) 2019-04-30 2020-04-29 がん関連抗体組成物および使用方法
CN202080048070.8A CN114127114A (zh) 2019-04-30 2020-04-29 癌相关抗体组合物和使用方法
US17/606,246 US20220204643A1 (en) 2019-04-30 2020-04-29 Cancer associated antibody compositions and methods of use
EP20798045.9A EP3962953A4 (fr) 2019-04-30 2020-04-29 Compositions d'anticorps associés au cancer et méthodes d'utilisation
CA3138550A CA3138550A1 (fr) 2019-04-30 2020-04-29 Compositions d'anticorps associes au cancer et methodes d'utilisation
AU2020266560A AU2020266560A1 (en) 2019-04-30 2020-04-29 Cancer associated antibody compositions and methods of use
IL287342A IL287342A (en) 2019-04-30 2021-10-18 Cancer associated antibody compositions and methods of use

Applications Claiming Priority (48)

Application Number Priority Date Filing Date Title
US201962840870P 2019-04-30 2019-04-30
US201962840861P 2019-04-30 2019-04-30
US201962841036P 2019-04-30 2019-04-30
US201962840950P 2019-04-30 2019-04-30
US201962840957P 2019-04-30 2019-04-30
US201962840644P 2019-04-30 2019-04-30
US201962840909P 2019-04-30 2019-04-30
US201962840864P 2019-04-30 2019-04-30
US201962840970P 2019-04-30 2019-04-30
US201962840917P 2019-04-30 2019-04-30
US201962840880P 2019-04-30 2019-04-30
US201962840855P 2019-04-30 2019-04-30
US201962840875P 2019-04-30 2019-04-30
US201962840638P 2019-04-30 2019-04-30
US201962840858P 2019-04-30 2019-04-30
US201962841047P 2019-04-30 2019-04-30
US201962841049P 2019-04-30 2019-04-30
US201962840648P 2019-04-30 2019-04-30
US201962840938P 2019-04-30 2019-04-30
US201962840893P 2019-04-30 2019-04-30
US201962841044P 2019-04-30 2019-04-30
US201962840860P 2019-04-30 2019-04-30
US201962840904P 2019-04-30 2019-04-30
US201962840640P 2019-04-30 2019-04-30
US62/840,893 2019-04-30
US62/840,858 2019-04-30
US62/840,970 2019-04-30
US62/841,036 2019-04-30
US62/840,957 2019-04-30
US62/840,938 2019-04-30
US62/841,049 2019-04-30
US62/840,870 2019-04-30
US62/840,904 2019-04-30
US62/841,047 2019-04-30
US62/841,044 2019-04-30
US62/840,638 2019-04-30
US62/840,917 2019-04-30
US62/840,909 2019-04-30
US62/840,644 2019-04-30
US62/840,864 2019-04-30
US62/840,648 2019-04-30
US62/840,640 2019-04-30
US62/840,860 2019-04-30
US62/840,875 2019-04-30
US62/840,855 2019-04-30
US62/840,861 2019-04-30
US62/840,950 2019-04-30
US62/840,880 2019-04-30

Publications (2)

Publication Number Publication Date
WO2020223392A2 WO2020223392A2 (fr) 2020-11-05
WO2020223392A3 true WO2020223392A3 (fr) 2020-12-10

Family

ID=73029242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/030534 WO2020223392A2 (fr) 2019-04-30 2020-04-29 Compositions d'anticorps associés au cancer et méthodes d'utilisation

Country Status (8)

Country Link
US (1) US20220204643A1 (fr)
EP (1) EP3962953A4 (fr)
JP (1) JP2022530667A (fr)
CN (1) CN114127114A (fr)
AU (1) AU2020266560A1 (fr)
CA (1) CA3138550A1 (fr)
SG (1) SG11202111672RA (fr)
WO (1) WO2020223392A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021395241A1 (en) * 2020-12-07 2023-06-22 Target Discovery Merger Sub II, LLC Systems and methods for producing disease-associated protein compositions
EP4291232A2 (fr) * 2021-02-12 2023-12-20 Merck Sharp & Dohme LLC Anticorps se liant au métapneumovirus, protéines de métapneumovirus antigéniques et leurs utilisations
CN117186218B (zh) * 2023-09-06 2024-04-30 十堰市太和医院（湖北医药学院附属医院） 一种靶向rbm47的纳米抗体及其制备方法
CN117625626B (zh) * 2024-01-25 2024-04-16 中国农业科学院植物保护研究所 RNAi在提高苏云金芽胞杆菌杀虫蛋白防治二化螟或草地贪夜蛾效果中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189964A2 (fr) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
US20190046611A1 (en) * 2017-08-03 2019-02-14 Amgen Inc. Interleukin-21 Muteins and Methods of Treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2580241B1 (fr) * 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Anticorps anti-annexine 1
US20140206574A1 (en) * 2011-08-31 2014-07-24 Karen Chapman Methods and Compositons for the Treatment and Diagnosis of Cancer
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
CA3051222C (fr) * 2013-06-10 2023-01-24 Dana-Farber Cancer Institute, Inc. Procedes et compositions pour reduire l'immunosuppression au moyen de cellules tumorales
US11040111B2 (en) * 2014-03-03 2021-06-22 Academia Sinica Bi-specific antibodies and uses thereof
JP2018507254A (ja) * 2015-02-02 2018-03-15 アイツー ファーマシューティカルズ， インコーポレーテッド 抗代替軽鎖抗体
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017189964A2 (fr) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
US20190046611A1 (en) * 2017-08-03 2019-02-14 Amgen Inc. Interleukin-21 Muteins and Methods of Treatment

Also Published As

Publication number Publication date
SG11202111672RA (en) 2021-11-29
CA3138550A1 (fr) 2020-11-05
EP3962953A2 (fr) 2022-03-09
WO2020223392A2 (fr) 2020-11-05
EP3962953A4 (fr) 2023-08-23
US20220204643A1 (en) 2022-06-30
JP2022530667A (ja) 2022-06-30
AU2020266560A1 (en) 2021-11-25
CN114127114A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
WO2020223392A3 (fr) Compositions d'anticorps associés au cancer et méthodes d'utilisation
EP4286415A3 (fr) Domaines de liaison à l'antigène humanisés dirigés contre les cd19 et leurs procédés d'utilisation
HRP20201090T1 (hr) Protutijela anti-icos
WO2017152102A3 (fr) Anticorps anti-trem1 et leurs méthodes d'utilisation
WO2017075432A3 (fr) Anticorps anti-siglec-9 et leurs procédés d'utilisation
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
WO2018057735A8 (fr) Anticorps pour siglec-15 et leurs méthodes d'utilisation
WO2020069184A3 (fr) Compositions et procédés de traitement du cancer par immunothérapie anti-cd19/cd22
EP3991748A3 (fr) Anticorps anti-sortiline et leurs procédés d'utilisation
WO2016201388A3 (fr) Anticorps anti-cd33 et leurs procédés d'utilisation
WO2016201389A3 (fr) Anticorps anti-cd33 et leurs procédés d'utilisation
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
WO2019060750A3 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
WO2021022083A3 (fr) Anticorps anti-ms4a4a et leurs procédés d'utilisation
MX2022011951A (es) Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
MX2022006709A (es) Anticuerpos antiidiotípicos para dominios de unión dirigidos a bcma y métodos y composiciones relacionadas.
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1
IL307417A (en) A chimeric antigen receptor comprising an anti-HER2 antibody or an antigen-binding fragment thereof and natural killer cells comprising the same
MX2022003833A (es) Anticuerpos anti-kir3dl3 y sus usos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20798045

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3138550

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021564804

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020266560

Country of ref document: AU

Date of ref document: 20200429

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020798045

Country of ref document: EP

Effective date: 20211130

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20798045

Country of ref document: EP

Kind code of ref document: A2